Abstract:Background: Tumor mutation burden (TMB) has been recognized as a predictive biomarker for immunotherapy response in cancer. Systematic identification of molecular features correlated with TMB is significant, although such investigation remains insufficient. Methods: We analyzed associations of somatic mutations, pathways, protein expression, microRNAs (miRNAs), long non-coding RNAs (lncRNAs), competing endogenous RNA (ceRNA) antitumor immune signatures, and clinical features with TMB in various cancers using multi-omics datasets from The Cancer Genome Atlas (TCGA) program and datasets for cancer cohorts receiving the immune checkpoint blockade therapy. Results: Among the 32 TCGA cancer types, melanoma harbored the highest percentage of high-TMB (≥ 10/Mb) cancers (49.4%), followed by lung adenocarcinoma (36.9%) and lung squamous cell carcinoma (28.1%). Three hundred seventy-six genes had significant correlations of their mutations with increased TMB in various cancers, including 11 genes ( ARID1A , ARID1B , BRIP1 , NOTCH2 , NOTCH4 , EPHA5 , ROS1 , FAT1 , SPEN , NSD1 ,and PTPRT ) with the characteristic of their mutations associated with a favorable response to immunotherapy. Based on the mutation profiles in three genes ( ROS1 , SPEN , and PTPRT ), we defined the TMB prognostic score that could predict cancer survival prognosis in the immunotherapy setting but not in the non-immunotherapy setting. It suggests that the TMB prognostic score's ability to predict cancer prognosis is associated with the positive correlation between immunotherapy response and TMB. Nine cancer-associated pathways correlated positively with TMB in various cancers, including nucleotide excision repair, DNA replication, homologous recombination, base excision repair, mismatch repair, cell cycle, spliceosome, proteasome, and RNA degradation. In contrast, seven pathways correlated inversely with TMB in multiple cancers, including Wnt, Hedgehog, PI3K-AKT, MAPK, neurotrophin, axon guidance, and pathways in cancer. High-TMB cancers displayed higher levels of antitumor immune signatures and PD-L1 expression than low-TMB cancers in diverse cancers. The association between TMB and survival prognosis was positive in bladder, gastric, and endometrial cancers and negative in liver and head and neck cancers. TMB also showed significant associations with age, gender, height, weight, smoking, and race in certain cohorts. Conclusions: The molecular and clinical features significantly associated with TMB could be valuable predictors for TMB and immunotherapy response and therefore have potential clinical values for cancer management.

Predicting Tumor Mutation Burden of TNBC Based on Nuclei Scores of Histopathological Images.

Tumor Mutation Burden Analysis in a 5,660 Cancer Patient Cohort Reveals Cancer Type-Specific Mechanisms for High Mutation Burden.

Integrated Analysis of Tumor Mutation Burden and Immune Infiltrates in Hepatocellular Carcinoma

Blood Tumor Mutation Burden Can Predict the Clinical Response to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Patients

Predicting Tumor Mutational Burden from Liver Cancer Pathological Images Using Convolutional Neural Network.

Pan-cancer Computational Histopathology Reveals Tumor Mutational Burden Status Through Weakly-Supervised Deep Learning.

Integrating Histologic and Genomic Characteristics to Predict Tumor Mutation Burden of Early-Stage Non-Small-Cell Lung Cancer

Deep learning-based approach to reveal tumor mutational burden status from whole slide images across multiple cancer types

Predicting Tumor Mutational Burden From Lung Adenocarcinoma Histopathological Images Using Deep Learning

Prediction of Tumor Mutation Load in Colorectal Cancer Histopathological Images Based on Deep Learning

Predicting Tumor Mutational Burden in Head and Neck Squamous Cell Carcinoma Based on CT Imaging Features: A TCGA/TCIA Study.

Single-cell and Bulk RNA Sequencing Analysis of B Cell Marker Genes in TNBC TME Landscape and Immunotherapy

A Six-Gene Signature Related with Tumor Mutation Burden for Predicting Lymph Node Metastasis in Breast Cancer

Development of Prognostic Biomarkers by TMB-Guided WSI Analysis: A Two-Step Approach

Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data

Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker

Predicting gastric cancer tumor mutational burden from histopathological images using multimodal deep learning

Model for predicting immunotherapy based on M2 macrophage infiltration in TNBC

[Multi-classification prediction model of lung cancer tumor mutation burden based on residual network]

Predicting patient outcomes (TNBC) based on positions of cancer islands and CD8+ T cells using machine learning approach

Graph-ETMB: A graph neural network-based model for tumour mutation burden estimation